Hemopoietic stem-cell harvesting and transplantation using G-CSF-primed BM: Comparison with unprimed BM and G-CSF-primed PBSC

Cytotherapy

Volumn 1, Issue 5, 1999, Pages 409-416

  Lowenthal, R M ^a   Tuck, D ^a   Tegg, E ^a   Marsden, K A ^a   Rees, B ^a   Luck, J ^a   Ragg, S ^a   Parker, N ^a,b   Kotlovsky, N ^a  

^a ROYAL HOBART HOSPITAL   (Australia)

^b Nicolaides and Partners   (Australia)

Author keywords

Bone marrow transplantation; G CSF; Peripheral blood stem cells; Stem cells

Indexed keywords

EID: 0000251769     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/0032472031000141285     Document Type: Article

References (43)

1. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353-7.
2. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997;15:5-10.
3. Bodine DM, Seidel NE, Orlic D. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood 1996;88:89-97.
4. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
5. Elbaz O, Budel LM, Hoogerbrugge H et al. Tumor necrosis factor down-regulates granulocyte-colony-simulating factor receptor expression on human acute myeloid leukaemia cella and granulocytes. J Clin Invest 1991; 87:838-41.
6. Begley CG, Metcalf D, Nicola NA. Binding characteristics and proliferative action of purified granulocyte colony-stimulating factor (G-CSF) on normal and leukemic human promylocytes. Exp Hematol 1988;16:71-9.
7. Metcalf D. Hemopoietic colonies: in vitro cloning of normal and leukemic cells. Recent Results Cancer Res 1977;61:1-227.
8. - cells cultured with interleukin-3, granulocyte colony stimulating factor, or granulocyte-macrophage colonystimulating factor. Blood 1991;77:2316-21.
9. + cell determination by flow cytometry. J Hetnatotherapy 1996;5:213-26.
10. To LB, Shepherd KM, Lam-Po-Tang R et al. Guidelines for the collection, processing, storage and of administration of hemopoietic stem and progenitor cells for transplantation. [Report of the working Party on Hemopoietic Stem Cell Processing, Hematology Discipline Advisory Committee, the Royal College of Pathologists of Australasia.] Pathology 1998;30:276-85.
11. Tegg EM, Tuck DM, Lowenthal RM, Mardsen KA. The effect of G-CSF on the composition of human bone marrow Clin Lab Haematol 1999;21:267-72.
12. Lowenthal RM, Fabères C, Marit G et al. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22:763-70.
13. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994;12:2176-86.
14. Ager S, Scott MA, Mahendra P et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16:79-83.
15. Janssen WE, Smilee RC:, Elfenbein GJ. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematotherapy 1995;4:139-40.
16. Dicke KA, Hood DL, Ameson M et al. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol 1997;25:34-8.
17. Weisdorf D, Miller J, Verfaillie C et al. Cytokine-primed bone marrow stern cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Biol Blood Marrow Transplant 1997;3:217-23.
18. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow, transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997;90:36-42.
19. Janssen WE. Mobilization of peripheral blood stem cells for autologous transplantation. Methods, mechanisms, and role in accelerating hematopoietic recovery. Ann N Y Acad Sci 1995;770: 116-29.
20. Knudsen LM, Hansen SW, Daugard G et al. Comparison of rhG-CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. Eur J Haematol 1998;61:229-34.
21. Stoppa AM, Blaise D, Viens P et al. Phase I study of in vivo lenograstim (rHuG-CSF) for stein cell collection demonstrates improved neutrophil recovery after autologous bone marrow, transplantation. Bone Marrow Transplant 1994;13:541-7.
22. Hansen PB, Knudsen H, Gaarsdal E et al. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. Bone Marrow Transplant 1995;16:373-9.
23. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640-4.
24. Klumpp TR, Mangan KF, Goldberg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13:1323-7.
25. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992; 79:1193-200.
26. Spitzer G, Adkins DR. Persistent problems of neutropenia and thrombocytopenia with peripheral blood stem cell transplantation. J Hematother 1994;3:193-8.
27. Becker PS, Wagle M, Matou S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997;3:45-9.
28. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353:555.
29. Duncan N, Hewetson M, Powles R et al. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow, transplantation in multiple myeloma. Bone Marrow Transplant 1996;18:1175-8.
30. + cells. Blood 1994;84: 2930-9.
31. Meisenberg B, Frakes L, Brehm T et al. Use of G-CSF given to allogeneic donors to improve CD34 yields in bone marrow collections and hasten engraftment. Blood 1996;299(Suppl 1): Abstract No. 1599.
32. Isola LM, Scigliano E, Skerrett D et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Born Marrow Transplant 1997;20:1033-7.
33. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999;94:455-64.
34. Appelbaum FR. Choosing the source of stem cells for allogeneic transplantation: no longer a peripheral issue. Blood 1999;94:381-3.
35. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999;94:384-9.
36. Marmont AM. Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 1998;83:733-43.
37. Potter M, Black C, Bone marrow transplantation for autoimmune diseases. Br Med J 1999;318:750-1.
38. Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40.
39. Voso MT, Murea S, Goldschmidt H et al. High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment. Br J Hemantol 1996;94:759-66.
40. Dhodapkar M, Goldberg SL, Tefferi A, Gertz MA. Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. Am J Hematol 1994;45:187-8.
41. Zambelli A, Poggi G, Da Prada G et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998;18:4705-8.
42. Verdeguer A, Bermudez M, De la Rubia J et al. Allogeneic PBPC transplantation in children. Cytotherapy 1999;1:195-201.
43. Nussbaumer W, Schönitzer D, Trieb T et al. Peripheral blood stem cell (PBSC) collection in extremely low-weight infants. Bone Marrow Transplant 1996;15-7.